
Craig D. Ricci
Examiner (ID: 10445, Phone: (571)270-5864 , Office: P/1628 )
| Most Active Art Unit | 1628 |
| Art Unit(s) | 1611, 1628, 1614 |
| Total Applications | 1547 |
| Issued Applications | 760 |
| Pending Applications | 153 |
| Abandoned Applications | 681 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16898941
[patent_doc_number] => 20210177857
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/183596
[patent_app_country] => US
[patent_app_date] => 2021-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44353
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17183596
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/183596 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | Feb 23, 2021 | Abandoned |
Array
(
[id] => 17198745
[patent_doc_number] => 20210338839
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/181187
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181187
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181187 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Feb 21, 2021 | Abandoned |
Array
(
[id] => 17035039
[patent_doc_number] => 20210251997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => PALIPERIDONE FOR TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISM SPECTRUM DISORDER
[patent_app_type] => utility
[patent_app_number] => 17/181716
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181716
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181716 | PALIPERIDONE FOR TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISM SPECTRUM DISORDER | Feb 21, 2021 | Abandoned |
Array
(
[id] => 17065033
[patent_doc_number] => 20210267248
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => Nutritional Compositions for Treating Cancer and Side Effects of Cancer Conventional Treatments
[patent_app_type] => utility
[patent_app_number] => 17/180804
[patent_app_country] => US
[patent_app_date] => 2021-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1198
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180804
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/180804 | Nutritional Compositions for Treating Cancer and Side Effects of Cancer Conventional Treatments | Feb 20, 2021 | Abandoned |
Array
(
[id] => 17035054
[patent_doc_number] => 20210252012
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity
[patent_app_type] => utility
[patent_app_number] => 17/176018
[patent_app_country] => US
[patent_app_date] => 2021-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176018
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176018 | Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity | Feb 14, 2021 | Abandoned |
Array
(
[id] => 16868415
[patent_doc_number] => 20210161882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => DEPOT ADMINISTRATION OF ILOPERIDONE
[patent_app_type] => utility
[patent_app_number] => 17/174730
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6478
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174730
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/174730 | DEPOT ADMINISTRATION OF ILOPERIDONE | Feb 11, 2021 | Abandoned |
Array
(
[id] => 18255966
[patent_doc_number] => 20230083005
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCER CELLS
[patent_app_type] => utility
[patent_app_number] => 17/798421
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31035
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -62
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798421
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/798421 | METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCER CELLS | Feb 11, 2021 | Pending |
Array
(
[id] => 18413094
[patent_doc_number] => 11667627
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Salt and crystal forms of PLK-4 inhibitor
[patent_app_type] => utility
[patent_app_number] => 17/172511
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 8886
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172511
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/172511 | Salt and crystal forms of PLK-4 inhibitor | Feb 9, 2021 | Issued |
Array
(
[id] => 18254798
[patent_doc_number] => 20230081837
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/798044
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24928
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798044
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/798044 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | Feb 4, 2021 | Abandoned |
Array
(
[id] => 16853435
[patent_doc_number] => 20210154180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => FORMULATION HAVING IMPROVED PH-DEPENDENT DRUG-RELEASE CHARACTERISTICS CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/167802
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5390
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 145
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17167802
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/167802 | FORMULATION HAVING IMPROVED PH-DEPENDENT DRUG-RELEASE CHARACTERISTICS CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Feb 3, 2021 | Abandoned |
Array
(
[id] => 16990100
[patent_doc_number] => 20210228520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => INTRAVENOUS BACLOFEN FORMULATIONS AND TREATMENT METHODS
[patent_app_type] => utility
[patent_app_number] => 17/164366
[patent_app_country] => US
[patent_app_date] => 2021-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2814
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17164366
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/164366 | INTRAVENOUS BACLOFEN FORMULATIONS AND TREATMENT METHODS | Jan 31, 2021 | Abandoned |
Array
(
[id] => 18237605
[patent_doc_number] => 20230069915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => PLANT DISEASE CONTROL COMPOSITION AND PLANT DISEASE CONTROL METHOD
[patent_app_type] => utility
[patent_app_number] => 17/759530
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18745
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759530
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/759530 | PLANT DISEASE CONTROL COMPOSITION AND PLANT DISEASE CONTROL METHOD | Jan 28, 2021 | Pending |
Array
(
[id] => 17005309
[patent_doc_number] => 20210236470
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
[patent_app_type] => utility
[patent_app_number] => 17/151582
[patent_app_country] => US
[patent_app_date] => 2021-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48250
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17151582
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/151582 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | Jan 17, 2021 | Abandoned |
Array
(
[id] => 17407125
[patent_doc_number] => 11247994
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-15
[patent_title] => 6-dithio-substituted-2'-deoxyguanosine compound, preparation method thereof and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/149747
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 6283
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 137
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149747
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/149747 | 6-dithio-substituted-2'-deoxyguanosine compound, preparation method thereof and use thereof | Jan 14, 2021 | Issued |
Array
(
[id] => 16977590
[patent_doc_number] => 20210221827
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => SOLID FORMS OF SUBSTITUTED BENZOXABOROLE AND COMPOSITIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/150809
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150809
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150809 | Solid forms of substituted benzoxaborole and compositions thereof | Jan 14, 2021 | Issued |
Array
(
[id] => 18134738
[patent_doc_number] => 11560391
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-24
[patent_title] => Sulfonylurea compounds as inhibitors of interleukin-1 activity
[patent_app_type] => utility
[patent_app_number] => 17/150380
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38059
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 436
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150380
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150380 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | Jan 14, 2021 | Issued |
Array
(
[id] => 16969263
[patent_doc_number] => 11065209
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-20
[patent_title] => Use of cannabidiol in the treatment of epilepsy
[patent_app_type] => utility
[patent_app_number] => 17/147005
[patent_app_country] => US
[patent_app_date] => 2021-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 5137
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147005
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/147005 | Use of cannabidiol in the treatment of epilepsy | Jan 11, 2021 | Issued |
Array
(
[id] => 18150201
[patent_doc_number] => 20230024058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => COMPOSITION THAT PROMOTE PRO-RESOLVING MEDIATORS
[patent_app_type] => utility
[patent_app_number] => 17/757409
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3483
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17757409
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/757409 | COMPOSITION THAT PROMOTE PRO-RESOLVING MEDIATORS | Jan 7, 2021 | Pending |
Array
(
[id] => 16791607
[patent_doc_number] => 20210121424
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => ANTIMICROBIAL COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/140760
[patent_app_country] => US
[patent_app_date] => 2021-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7675
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17140760
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/140760 | Antimicrobial composition | Jan 3, 2021 | Issued |
Array
(
[id] => 20437416
[patent_doc_number] => 12508237
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-30
[patent_title] => Pharmaceutical composition comprising 4-hexylresorcinol as active ingredient for prevention or treatment of bone disease
[patent_app_type] => utility
[patent_app_number] => 17/790132
[patent_app_country] => US
[patent_app_date] => 2020-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 0
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17790132
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/790132 | Pharmaceutical composition comprising 4-hexylresorcinol as active ingredient for prevention or treatment of bone disease | Dec 27, 2020 | Issued |